The influence of elevated liver function parameters on the pharmacokinetics of doxorubicin and epirubicin--a population based pharmacokinetic study of CESAR-APOH. Central European Society for Anticancer Drug Research. Working Group for Pharmacology in Oncology and Hematology

Int J Clin Pharmacol Ther. 2002 Dec;40(12):575-7. doi: 10.5414/cpp40575.
No abstract available

Publication types

  • Clinical Trial
  • Comparative Study
  • Multicenter Study

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Antibiotics, Antineoplastic / administration & dosage
  • Antibiotics, Antineoplastic / adverse effects
  • Antibiotics, Antineoplastic / pharmacokinetics*
  • Chromatography, High Pressure Liquid
  • Dose-Response Relationship, Drug
  • Doxorubicin / administration & dosage
  • Doxorubicin / adverse effects
  • Doxorubicin / pharmacokinetics*
  • Epirubicin / administration & dosage
  • Epirubicin / adverse effects
  • Epirubicin / pharmacokinetics
  • Female
  • Humans
  • Infusions, Intravenous
  • Liver / metabolism
  • Liver Neoplasms / metabolism
  • Liver Neoplasms / secondary
  • Male
  • Middle Aged
  • Prospective Studies

Substances

  • Antibiotics, Antineoplastic
  • Epirubicin
  • Doxorubicin